NCT03494322View on ClinicalTrials.gov

EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

July 20, 2018

Primary Completion Date

September 15, 2021

Study Completion Date

October 31, 2024

Conditions
Head and Neck CancerSquamous Cell Carcinoma
Interventions
DRUG

Avelumab

Avelumab 10 mg/kg given IV

DRUG

Cetuximab

"Cetuximab 500\* mg/m2 given IV~\*Cetuximab dose will be dependent on outcome of safety run-in."

Trial Locations (1)

NW1 2PG

University College Hospital, London

All Listed Sponsors
collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

University College, London

OTHER